- Trillium Therapeutics (TSX:TRIL) has announced it has dosed the first patient in its Phase 1b/2 study of TTI-622 in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (AML)
- TTI-622 is a fusion protein intended to block the inhibitory activity of CD42, which is a molecule that is overexpressed by a wide range of tumors
- Preclinical studies of TTI-622 has sown anti-tumor activity exhibits against AML cells as a monotherapy that is enhanced when it is combined with azacitidine or ventetoclax
- At least 50 elderly patients aged 75 or older who are unfit for intensive induction chemotherapy newly diagnosed with TP53-wild type AML will be enrolled
- Primary endpoints of the study include safety and complete response rate
- Shares of Trillium Therapeutics were down 4.34 per cent to C$11.25 as of 2:51 p.m. EDT
Trillium Therapeutics (TRIL) has announced it has dosed the first AML patient in its Phase 1b/2 study of TTI-622 in combination with azacitidine and venetoclax.
TTI-622 is a fusion protein intended to block the inhibitory activity of CD42, which is a molecule that is overexpressed by a wide range of tumours.
“The dosing of this patient marks the second combination cohort that has been initiated with TTI-622,” Dr. Ingmar Bruns, Chief Medical Officer of Trillium, said in a press release. “AML is an important part of a Phase 1b/2 program we initiated to evaluate TTI-622 with various combination agents in five hematologic malignancy and solid tumor indications, building upon the monotherapy activity that we have observed in multiple hematologic cancers.”
According to the release, preclinical studies of TTI-622 have shown anti-tumour activity exhibits against AML cells as a monotherapy enhanced when combined with azacitidine or ventetoclax, which is being assessed as part of an ongoing open-label study.
Roughly 50 patients aged 75 or older with newly diagnosed TP53-wild type AML will be enrolled who are unfit for intensive induction chemotherapy.
The primary endpoints of the study include safety and complete response rate.
“We believe that the combination of TTI-622 and azacitidine and venetoclax has strong potential to address this population and have a significant impact on the frontline AML treatment landscape, if approved,” Dr. Bruns added.
In addition to this clinical program, Trillium has an additional clinical program for TTI-621. Between the two clinical programs, the company anticipates generating a strong flow of data over the next several years.
Shares of Trillium Therapeutics were down 4.34 per cent to C$11.25 as of 2:51 p.m. EDT.
